Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on its application for orphan drug designation for CDNF as a potential treatment for amyotrophic lateral sclerosis (ALS).
A positive opinion is the first step toward orphan drug designation which, in Europe, is issued by the European Commission.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?